



5

10

5

20

25

Sub AZ 25 Sub CI

7. A pharmaceutical composition that comprises as an active

ingredient the DNA of claim 1 or 2, or the protein of claim 6.

8. A pharmaceutical composition for treating or preventing tumors, which comprises as an active ingredient the DNA of claim 1 or 2, or the protein of claim 6.

9. A tumor antigen peptide that is a partial peptide derived from the protein of claim 6, and that is capable of binding to an HLA antigen and being recognized by cytotoxic T lymphocytes, or a derivative thereof having the functionally equivalent properties.

10. The tumor antigen peptide of claim 9 wherein the HLA antigen is HLA-A24, or a derivative thereof having the functionally equivalent properties.

11. The tumor antigen peptide of claim 10, which comprises a sequence selected from all or part of an amino acid sequence shown in any one of SEQ ID NOs: 3-18, or a derivative thereof having the functionally equivalent properties.

12. The tumor antigen peptide of claim 11, which comprises a sequence selected from all or part of an amino acid sequence shown in any one of SEQ ID NOs: 3-5, or a derivative thereof having the functionally equivalent properties.

13. The tumor antigen peptide derivative of claim 11, which comprises a sequence selected from all or part of an amino acid sequence shown in any one of SEQ ID NOs: 3-18 wherein the amino acid residue at position 2 and/or the C-terminus is substituted by "another amino acid residue." WD

14. The tumor antigen peptide derivative of claim 13, which comprises a sequence selected from all or part of an amino acid

Sub  
C1

05057308-060101

Sub  
A3

Sub C3

25  
Sub  
A4

18. A recombinant DNA comprising at least one of DNAs that  
the tumor antigen peptides or derivatives thereof according to  
of claims 9 to 16.

20. A pharmaceutical composition for treating or preventing  
which comprises as an active ingredient the recombinant DNA  
18 or the recombinant polypeptide of claim 19.

21. An antibody that specifically binds to any one of the

protein of claim 6, and the tumor antigen peptide or the derivative thereof according to any one of claims 9 to 16.

22. An antigen-presenting cell wherein a complex between an HLA antigen and the tumor antigen peptide or the derivative thereof according to any one of claims 9 to 16 is presented on the surface of a cell having antigen-presenting ability, which cell is isolated from a tumor patient.

23. An antigen-presenting cell on which a complex between an HLA antigen and a tumor antigen peptide or a derivative thereof is presented, said antigen-presenting cell being obtainable by allowing a cell having antigen-presenting ability isolated from a tumor patient to be incorporated with the DNA of claim 1 or 2, the tumor antigen protein of claim 6, the recombinant DNA of claim 18, or the recombinant polypeptide of claim 19.

24. A pharmaceutical composition for treating tumors, which comprises as an active ingredient the antigen-presenting cell of claim 22 or 23.

25. A cytotoxic T lymphocyte that specifically recognizes a complex between an HLA antigen and the tumor antigen peptide or derivative thereof according to any one of claims 9 to 16.

26. A cytotoxic T lymphocyte that specifically recognizes a complex between an HLA antigen and a tumor antigen peptide or derivative thereof, which complex is presented on the antigen-presenting cell of claim 22 or 23.

27. A pharmaceutical composition for treating tumors, which comprises as an active ingredient the cytotoxic T lymphocyte of claim

Sub  
A4

5

05057308-060101

10

15

Sub  
A5

20

25

Sub  
A1  
25 or 26.

Sub  
A6  
5  
28. A diagnostic agent for tumors, which comprises the tumor antigen peptide or derivative thereof according to any one of claims 9 to 16, the protein of claim 6, or the recombinant polypeptide of claim 19.

09857308 .060101